Terms: = Breast cancer AND CD74, ENSG00000019582, 972, protein 41, Ia-GAMMA, HLADG, DHLAG
274 results:
1. Immunohistochemical study of cd74 biomarker in normal and malignant breast tissues.
Hassan HN; Al-Hussein RKA; Al-Naqeeb AA
Pol Merkur Lekarski; 2024; 52(2):233-239. PubMed ID: 38642360
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic impact of metabolic syndrome in patients with primary endometrial cancer: a retrospective bicentric study.
Shehaj I; Krajnak S; Rad MT; Gasimli B; Hasenburg A; Karn T; Schmidt M; Müller V; Becker S; Gasimli K
J Cancer Res Clin Oncol; 2024 Apr; 150(4):174. PubMed ID: 38570343
[TBL] [Abstract] [Full Text] [Related]
3. Adjuvant chemotherapy and survival in males aged 70 years or older with breast cancer: a population-based retrospective study.
Yu Y; Huang K; Liu Y; Chen R; Yu X; Song C
BMC Geriatr; 2024 Mar; 24(1):282. PubMed ID: 38528444
[TBL] [Abstract] [Full Text] [Related]
4. Cost-effectiveness of one-year adjuvant trastuzumab therapy in treatment for early-stage breast cancer patients with HER2+ in Vietnam.
Nguyen AQ; Tran OTM; Nguyen PK; Nguyen HT
PLoS One; 2024; 19(3):e0300474. PubMed ID: 38489305
[TBL] [Abstract] [Full Text] [Related]
5. Neoadjuvant chemotherapy for breast cancer: Pathologic response rates but not tumor size, has an independent prognostic impact on survival.
Houvenaeghel G; de Nonneville A; Cohen M; Sabiani L; Buttarelli M; Charaffe E; Jalaguier A; Bannier M; Tallet A; Viret F; Gonçalves A
Cancer Med; 2024 Feb; 13(3):e6930. PubMed ID: 38327130
[TBL] [Abstract] [Full Text] [Related]
6. Effects of Extended Fixation on Advanced Gastric cancer HER2 Status Assessment Using IHC and FISH.
Kondo J; Yoshino S; Iida M; Takeda S; Nakashima C; Watanabe Y; Nishiyama M; Tokumitsu Y; Shindo Y; Nishimura T; Suzuki N; Hoshii Y; Itoh H; Nagano H
Anticancer Res; 2024 Feb; 44(2):621-630. PubMed ID: 38307565
[TBL] [Abstract] [Full Text] [Related]
7. Ki-67 Change in Anthracyline-containing Neoadjuvant Chemotherapy Response in breast cancer.
Yang ZG; Ren LH; Wang F; Wang PL; Wang WY; Lin SY
Curr Med Sci; 2024 Feb; 44(1):156-167. PubMed ID: 38302780
[TBL] [Abstract] [Full Text] [Related]
8. PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores.
Ivanova M; Frascarelli C; Cerbelli B; Pignataro MG; Pernazza A; Venetis K; Sajjadi E; Criscitiello C; Curigliano G; Guerini-Rocco E; Graziano P; Martini M; d'Amati G; Fusco N
Hum Pathol; 2024 Feb; 144():22-27. PubMed ID: 38278450
[TBL] [Abstract] [Full Text] [Related]
9. Refining breast cancer biomarker discovery and drug targeting through an advanced data-driven approach.
Rakhshaninejad M; Fathian M; Shirkoohi R; Barzinpour F; Gandomi AH
BMC Bioinformatics; 2024 Jan; 25(1):33. PubMed ID: 38253993
[TBL] [Abstract] [Full Text] [Related]
10. The Association between ER, PR, HER2, and ER-/PR+ Expression and Lung cancer Subsequent in breast cancer Patients: A Retrospective Cohort Study Based on SEER Database.
Shao HY; Hao BT; Gao FX
Breast J; 2023; 2023():7028189. PubMed ID: 38021219
[TBL] [Abstract] [Full Text] [Related]
11. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels the heterogeneity of cancer-associated fibroblasts in TNBC.
Wu X; Lu W; Zhang W; Zhang D; Mei H; Zhang M; Cui Y; Zhuo Z
Aging (Albany NY); 2023 Nov; 15(21):12674-12697. PubMed ID: 37963845
[TBL] [Abstract] [Full Text] [Related]
12. Analysis of cd74 Occurrence in Oncogenic Fusion proteins.
Vargas J; Pantouris G
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958963
[TBL] [Abstract] [Full Text] [Related]
13. Pathology of MRI and second-look ultrasound detected multifocal breast cancer.
Su S; Ray JC; Ooi C; Jain M
Acta Oncol; 2023 Dec; 62(12):1840-1845. PubMed ID: 37890095
[TBL] [Abstract] [Full Text] [Related]
14. The prognostic impact of BMI in patients with HR+/HER2- advanced breast cancer: a study of the SONABRE registry.
Lammers SWM; Thurisch H; Vriens IJH; Meegdes M; Engelen SME; Erdkamp FLG; Dercksen MW; Vriens BEPJ; Aaldering KNA; Pepels MJAE; van de Winkel LMH; Peters NAJB; Tol J; Heijns JB; van de Wouw AJ; Teeuwen NJA; Geurts SME; Tjan-Heijnen VCG
Breast Cancer Res Treat; 2024 Jan; 203(2):339-349. PubMed ID: 37878148
[TBL] [Abstract] [Full Text] [Related]
15. Similarities and discrepancies between commercially available bioelectrical impedance analysis system and dual-energy X-ray absorptiometry for body composition assessment in 10-14-year-old children.
Ohara K; Nakamura H; Kouda K; Fujita Y; Mase T; Momoi K; Nishiyama T
Sci Rep; 2023 Oct; 13(1):17420. PubMed ID: 37833453
[TBL] [Abstract] [Full Text] [Related]
16. Diagnostic Accuracy of Ultrasound in the Diagnosis of Uterine Leiomyomas and Sarcomas.
Raffone A; Raimondo D; Neola D; Travaglino A; Raspollini A; Giorgi M; Santoro A; De Meis L; Zannoni GF; Seracchioli R; Casadio P; Guida M
J Minim Invasive Gynecol; 2024 Jan; 31(1):28-36.e1. PubMed ID: 37778636
[TBL] [Abstract] [Full Text] [Related]
17. New cancer Diagnoses Before and During the COVID-19 Pandemic.
Decker KM; Feely A; Bucher O; Czaykowski P; Hebbard P; Kim JO; Pitz M; Singh H; Thiessen M; Lambert P
JAMA Netw Open; 2023 Sep; 6(9):e2332363. PubMed ID: 37669049
[TBL] [Abstract] [Full Text] [Related]
18. An endoplasmic reticulum stress-related signature could robustly predict prognosis and closely associate with response to immunotherapy in pancreatic ductal adenocarcinoma.
Liu S; Hu Q; Xie Z; Chen S; Li Y; Quan N; Huang K; Li R; Fang L
J Cancer Res Clin Oncol; 2023 Nov; 149(17):15589-15608. PubMed ID: 37653101
[TBL] [Abstract] [Full Text] [Related]
19. Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients.
Chen Z; Jia H; Zhang H; Chen L; Zhao P; Zhao J; Fu G; Xing X; Li Y; Wang C
Breast Cancer Res Treat; 2023 Nov; 202(2):313-323. PubMed ID: 37639064
[TBL] [Abstract] [Full Text] [Related]
20. MATH: A Deep Learning Approach in QSAR for Estrogen Receptor Alpha Inhibitors.
Pusparini RT; Krisnadhi AA; Firdayani
Molecules; 2023 Aug; 28(15):. PubMed ID: 37570812
[TBL] [Abstract] [Full Text] [Related]
[Next]
